insitro and Xaira Converging in Biologics

The real shift is that antibody design turns Xaira from a data and target discovery peer into a direct modality peer. insitro has been moving beyond small molecules and oligos into biologics through its CombinAbleAI acquisition and Lilly work on antibody based therapeutics, while Xaira is now showing de novo antibody design tied to its own pipeline. That makes the competitive question less about who has the broader platform story, and more about whose programs produce better drug candidates faster.1 2 3 4 5

• insitro’s biologics push is concrete, not just conceptual. It acquired CombinAbleAI to add TherML and make its design stack modality agnostic, and Lilly has already partnered with insitro on a program that includes an antibody therapeutic against an insitro discovered target.2 3
• Xaira is not just predicting structures. It describes a workflow that starts with a target epitope, generates antibody candidates from scratch, then scores them for affinity, stability, manufacturability, and immunogenicity before wet lab testing. That is the same part of the workflow where insitro now aims to compete in biologics.4 5
• The overlap also narrows the gap with Isomorphic Labs. Isomorphic says its engine is being used across small molecules, antibodies, peptides, and other modalities, which means all three companies are converging on the same integrated pitch of target understanding plus molecule design plus internal pipeline ownership.6 7

Going forward, platform narratives will matter less than program evidence. As antibody design spreads across AI drug companies, differentiation moves to whether each company can turn model output into progressable biologics, meaning molecules that bind the target, survive manufacturing, and keep advancing into the clinic.4 5 7